Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Grit Andersen"'
Autor:
Grit Andersen, Rosy Eloy, Susanne Famulla, Tim Heise, Grégory Meiffren, Cyril Seroussi, Martin Gaudier, Claire Mégret, You‐Ping Chan, Olivier Soula, Matthew Riddle
Publikováno v:
Diabetes, Obesity and Metabolism. 25
Autor:
null Grit Andersen, null Gursharan Singh, null Sundara Moorthi Nainar Murugesan, null Rajesh Gogineni, null Nirant Sharma, null Jayanti Panda, null Ashwani Marwah, null Subramanian Loganathan, null Sandeep N Athalye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4779f6cfc4e1cfecba7e2dd73a99fb48
https://doi.org/10.1111/dom.14994/v2/response1
https://doi.org/10.1111/dom.14994/v2/response1
Autor:
null Grit Andersen, null Rosy Eloy, null Susanne Famulla, null Tim Heise, null Grégory Meiffren, null Cyril Seroussi, null Martin Gaudier, null Claire Mégret, null You‐Ping Chan, null Olivier Soula, null Matthew Riddle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ed92bd5dfed53094ecd117ff0d8208e
https://doi.org/10.1111/dom.14972/v2/response1
https://doi.org/10.1111/dom.14972/v2/response1
Autor:
Theresa Herbrand, Bruno Poirier, Philip Janiak, Anthony J. Muslin, Paul Deutsch, Hans Veit Coester, Xavier Benain, Lionel Hovsepian, Luc Bergougnan, Maria Francesca Evaristi, Ashfaq Parkar, Jorge Arrubla, Rania Boiron, Grit Andersen, Olivier Vitse, Agnes Tardat, Roberto Sansone, Stephane Kirkesseli, Christian Heiss, Radzik Davide, Leona Plum-Mörschel, Marcel Ermer, Fabrice Hurbin
Publikováno v:
British Journal of Clinical Pharmacology
AIMS SAR247799 is a G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist designed to activate endothelial S1P1 and provide endothelial-protective properties, while limiting S1P1 desensitization and consequent lymphocyte-count reduction
Autor:
Helle Linnebjerg, Elizabeth Smith Labell, Grit Andersen, Tim Heise, Eric Zijlstra, Lidia Hermanski, Leszek Nosek, Mary Anne Dellva, David E. Coutant, Jennifer Leohr
Publikováno v:
Clinical Pharmacokinetics
Background and objective Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This study compared the insulin lispro pharmacokinetics
Autor:
Lars Johansson, Grit Andersen, Rohit Loomba, Mads Sundby Palle, Anni Morsing, Leona Plum-Mörschel, Paul D. Hockings, Anne Flint, Thomas J. Vogl
Publikováno v:
Alimentary pharmacology & therapeutics, vol 54, iss 9
BackgroundGlucagon-like peptide-1 receptor agonists may be a treatment option in patients with non-alcoholic fatty liver disease (NAFLD).AimsTo investigate the effects of semaglutide on liver stiffness and liver fat in subjects with NAFLD using non-i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e5c7e57c718aa14129e2339ea0af88d
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/64497
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/64497
Autor:
Claire Mégret, You-Ping Chan, Rosy Eloy, Grit Andersen, J. Hans DeVries, Grégory Meiffren, Olivier Soula, Martin Gaudier, Cyril Seroussi, Tim Heise, Susanne Famulla
Publikováno v:
Diabetes. 70
ADO09 is a co-formulation of Pram and insulin A21G developed to deliver the positive effects of Pram without additional injections. This double-blind randomized cross-over trial investigated the effects of pre-meal ADO09 vs. insulin aspart (ASP) on m
Autor:
Grit Andersen, Grégory Meiffren, Susanne Famulla, Tim Heise, Aymeric Ranson, Cyril Seroussi, Rosy Eloy, Martin Gaudier, Richard Charvet, You‐Ping Chan, Olivier Soula, J. Hans DeVries
Publikováno v:
Diabetes, Obesity and Metabolism. 23
Autor:
Grégory Meiffren, Grit Andersen, J. Hans DeVries, Olivier Soula, Susanne Famulla, Richard Charvet, Martin Gaudier, Tim Heise, Aymeric Ranson, Rosy Eloy, You-Ping Chan, Cyril Seroussi
Publikováno v:
Diabetes, obesity & metabolism, 23(4), 961-970. Wiley-Blackwell
Aim: To compare the safety, pharmacokinetics and pharmacodynamics of ADO09 with insulin lispro (Lispro) and separate subcutaneous injections of human insulin and pramlintide (Ins&Pram) in 24 subjects with type 1 diabetes. Methods: At three dosing vis
Autor:
Martin Gaudier, Susanne Famulla, Cyril Seroussi, Rosy Eloy, Grégory Meiffren, Grit Andersen, Richard Charvet, Olivier Soula, Tim Heise, J. Hans DeVries, Aymeric Ranson, You-Ping Chan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53b092835fde852201dee76db3559eee
https://doi.org/10.1111/dom.14302/v2/response1
https://doi.org/10.1111/dom.14302/v2/response1